RNA therapeutics represent a profound paradigm shift in medicine. Instead of designing complex small molecules to fit into the highly specific pockets of disease-associated proteins, we can use programmable genetic sequences—such as small interfering RNAs (siRNAs), microRNAs (miRNAs), or messenger RNAs (mRNAs)—to selectively silence, restore, or express virtually any protein of interest.
In vitro, this approach works beautifully. For instance, W.K. Yip et al. demonstrated how restoring suppressed microRNA transcription programs can halt hepatocellular carcinoma development in Carboxyl-Terminal Truncated HBx Regulates a Distinct MicroRNA Transcription Program in Hepatocellular Carcinoma Development. Similarly, Michael W.Y. Chan et al. showed in Targeted inhibition of COX-2 expression by RNA interference suppresses tumor growth and potentiates chemosensitivity to cisplatin in human gastric cancer cells that siRNA-mediated knockdown of specific inflammatory enzymes effectively sensitizes gastric cancer cells to chemotherapy.
Yet, translating these discoveries into living organisms faces a massive bioengineering bottleneck: the delivery problem. To make RNA therapeutics clinically viable, researchers must engineer precision vehicles capable of navigating a gauntlet of physiological barriers.
The Anatomy of the Delivery Barrier
Why does RNA struggle to reach its destination? When introduced into the bloodstream, naked RNA molecules face immediate destruction by circulating nucleases. If they survive enzymatic degradation, their size and charge profile cause them to be rapidly cleared by the kidneys or non-specifically sequestered by the liver's filtration systems.
As Mirjana Mačvanin et al. emphasize in Diabetic cardiomyopathy: The role of microRNAs and long non-coding RNAs, an inability to target specific tissues causes therapeutic payloads to accumulate in unintended organs, generating systemic toxicity while diluting the dose that reaches the diseased site.
To solve this, bioengineers must overcome three distinct scales of delivery barriers:
1. The Macro Scale: Systemic vs. Localized Transport
Localized delivery systems, such as the injectable hydrogels developed by Jiahui Du et al. in BRD9-mediated chromatin remodeling suppresses osteoclastogenesis through negative feedback mechanism, can successfully maintain high therapeutic concentrations within a single joint or bone defect. However, local administration cannot address systemic skeletal disorders or widespread metastatic disease.
Conversely, relying on direct intratumoral injections—as explored by Hao Li in Fn-OMV potentiates ZBP1-mediated PANoptosis triggered by oncolytic HSV-1 to fuel antitumor immunity—restricts treatment to accessible primary tumors, leaving internal or widely disseminated lesions untouched. Systemic transport is required, but it demands sophisticated molecular guidance.
2. The Micro Scale: Cellular Heterogeneity
Even if a delivery vehicle successfully accumulates within a target organ, it must navigate a complex cellular mosaic. In the brain, for example, Yayi Jiang et al. note in Bridging metabolic syndrome and cognitive dysfunction: role of astrocytes that therapies targeting metabolic cognitive decline must precisely enter astrocytes without altering neighboring neurons or vascular networks.
Similarly, Yongchao Zhao points out in m7G Methyltransferase METTL1 Promotes Post-ischemic Angiogenesis via Promoting VEGFA mRNA Translation that therapeutic modulation of blood vessel growth requires isolating endothelial cells within highly complex tissue environments to prevent dangerous off-target vascular remodeling elsewhere.
3. The Nano Scale: Subcellular Localization
The journey does not end at the cell membrane. To function, RNA must enter the correct intracellular compartment. As Ting Wang et al. explain in Immunogenic sonodynamic therapy for inducing immunogenic cell death and activating antitumor immunity, triggering the systemic immune stress signals required to fight tumors requires therapeutic agents to localize precisely to specific organelles, such as the endoplasmic reticulum. Without this subcellular precision, the molecule cannot activate the necessary downstream pathways.
Mechanisms of Precision Delivery
To bypass these multi-scale barriers, researchers are shifting away from passive delivery and toward actively engineered vehicles. These platforms use chemical, biomimetic, and genetic modifications to change how the body interacts with therapeutic cargo.
[Systemic Circulation]
│
▼ (Challenge: Nuclease Degradation & Liver Clearance)
[Engineered Vehicle (LNP / Exosome / Nanopore)]
│
▼ (Mechanism: Surface Ligands / Hydrophobic Anchors)
[Cell-Specific Uptake (Endothelial, Astrocyte, Fibroblast)]
│
▼ (Mechanism: Endosomal Escape / Organelle Targeting)
[Precision Intracellular Action]
Surface-Engineered Lipid Nanoparticles (LNPs)
Lipid nanoparticles are highly effective at encapsulating fragile RNA, but standard formulations naturally adsorb blood proteins that direct them straight to the liver. To alter this innate tropism, engineers modify the chemical structure of the lipid shell.
In LPA1 antagonist-derived LNPs deliver A20 mRNA and promote anti-fibrotic activities, Diana D. Kang et al. developed specialized LNPs that bypass standard hepatic clearance to deliver anti-fibrotic mRNA directly to lung fibroblasts. By tuning the surface properties, the authors successfully redirected the nanoparticles to home into deep lung tissue, offering a blueprint for treating idiopathic pulmonary fibrosis.
Biomimetic Exosomes and Synthetic Nanopores
Rather than building vehicles entirely from scratch, some strategies leverage natural cellular communication channels. As reviewed by Yongfeng Yang et al. in Roles of exosomes and exosome-derived miRNAs in pulmonary fibrosis, cell-derived vesicles called exosomes possess innate biocompatibility and surface proteins that allow them to cross biological membranes more efficiently than synthetic alternatives.
To achieve a similar advantage synthetically, Yuan Li et al. engineered DNA-based nanopores in Ethane groups modified DNA nanopores to prolong the dwell time on live cell membranes for transmembrane transport. By modifying these synthetic structures with hydrophobic ethane groups, the authors increased the pore's "dwell time" within live cell membranes. This physical anchor allows the nanopores to act as stable conduits that facilitate direct transmembrane transport, effectively bypassing the active efflux pumps that cancer cells use to reject foreign molecules.
Capsid and Promoter Engineering
When viral vectors like Adeno-associated viruses (AAVs) are used to deliver genetic machinery, they frequently encounter cellular resistance. Immune cells, such as microglia, are notoriously difficult to transduce.
To overcome this cellular defense, Jie Yin et al. argue in P300-Targeted Acetylome Reveals a Role for HMGB1 Translocation in Central Cardiac Sympathetic Activation Post Myocardial Infarction that researchers must engineer specialized viral capsids paired with cell-specific promoters. Even if a vector enters multiple cell types, a cell-specific promoter ensures that the therapeutic RNA is only transcribed inside the exact target cell population, adding a crucial layer of genetic safety.
The Path Forward
The transition from identifying an RNA target to achieving clinical success hinges entirely on the precision of the delivery vehicle. As synthesized by Shankar Subramaniam et al. in Grand Challenges at the Interface of Engineering and Medicine, the ultimate goal of biomedical engineering is to establish safe, redosable, and tissue-specific delivery systems. By systematically dismantling the macro, micro, and nano-scale barriers to transport, these engineered platforms are turning the theoretical promise of programmable RNA therapeutics into highly targeted clinical realities.